At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,584 enrolled
Drug / intervention
Rivastigmine 5 cm^2 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline
In Brief
A Phase 3 clinical trial evaluating Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, and 3 other interventions for Alzheimer Disease. Completed, enrolled 1,584 participants across 145 sites in 7 countries.
Detailed Summary
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesCanada, France, Germany, Italy, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJul 2007
Primary CompletionMay 2011
TodayJul 2026
First PostedJul 25, 2007
Enrollment StartJun 1, 2007
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.9 years ago
Interventions
Rivastigmine 5 cm^2drug
5 cm\^2 transdermal patch
Rivastigmine 10 cm^2drug
10 cm\^2 transdermal patch.
Rivastigmine 15 cm^2drug
15 cm\^2 transdermal patch.
Placebo to 15 cm^2 patchdrug
Placebo of rivastigmine transdermal patch 15 cm\^2.
Placebo to 10 cm^2 patchdrug
Placebo of rivastigmine transdermal patch 10 cm\^2.